The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.